Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03263442 · ClinicalTrials.gov registry record · Phase 2
High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation
A Phase 2 study of Delirium and Hematopoietic Stem Cell Transplantation, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
- 1
- Study location
NCT03263442 is a Phase 2 study of Delirium and Hematopoietic Stem Cell Transplantation that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 66 participants, below the 887-participant average among 62 other Delirium trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03263442, a Phase 2 study of Delirium and Hematopoietic Stem Cell Transplantation, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
- 1
- Study location
Study Summary
Purpose: To conduct a randomized controlled pilot study investigating the use of high dose intravenous (IV) thiamine to prevent delirium and mitigate the long-term effects of delirium, including health-related quality of life (HRQOL), functional status, and neuropsychiatric outcomes, in patients admitted to University of North Carolina (UNC) Hospital for allogeneic hematopoietic stem cell transplant (HSCT). Participants: 60 adult inpatients admitted to the UNC Bone Marrow Transplant Unit for allogeneic stem cell transplant. Procedures (methods): Participants will be admitted for allogeneic HSCT and on the day after transplant randomized to seven days of high dose IV thiamine or placebo. Thiamine levels will be measured weekly and participants will be assessed for evidence of delirium using validated measures. Validated measures will also be used to assess cognitive function, depression, post-traumatic stress symptoms, functional status, and HRQOL prior to hospitalization and at one, three, and six months after transplant.
Conditions Studied
Interventions
- DRUG Normal saline
- DRUG Thiamine
Study Locations (1)
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2017-10-16 |
| Est. Completion | 2020-08-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03263442
The ClinicalTrials.gov registry entry for NCT03263442 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 887-participant average among 62 other Delirium trials with a reported enrollment target (93% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Delirium appearing as the primary indexed condition, and to 2 interventions - of which Normal saline is the first listed.
NCT03263442 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT03263442 about?
NCT03263442 is a clinical study titled "High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation". Purpose: To conduct a randomized controlled pilot study investigating the use of high dose intravenous (IV) thiamine to prevent delirium and mitigate the long-term effects of delirium, including health-related quality of life (HRQOL), functional status, and neuropsychiatric outcomes, in patients adm...
What is the current status of trial NCT03263442?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2017-10-16. Estimated completion is 2020-08-10.
What conditions does trial NCT03263442 study?
This clinical trial studies the following conditions: Delirium, Hematopoietic Stem Cell Transplantation, Thiamine Deficiency.
What interventions are being tested in trial NCT03263442?
The interventions under investigation include: Normal saline (DRUG), Thiamine (DRUG).
Who is sponsoring clinical trial NCT03263442?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03263442 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Delirium
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy
RECRUITING · Phase 2
-
Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care
ACTIVE NOT RECRUITING · Phase 2
-
Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Care.Coach Avatars for Improvement of Outcomes in Hospitalized Elders, Including Mitigation of Falls and Delirium: a Multi-Site Clinical Study
COMPLETED · Phase 2
-
Investigation of Sleep in the Intensive Care Unit
COMPLETED · Phase 2
-
The Impact of Ketamine on Postoperative Cognitive Dysfunction, Delirium, and Renal Dysfunction
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.